Androgen Receptor Protein
Overview
The androgen receptor (AR) is a ligand-activated nuclear receptor that mediates the physiological effects of androgens, primarily testosterone and dihydrotestosterone (DHT), in target tissues throughout the body. The AR protein is encoded by the AR gene located on the X chromosome and belongs to the steroid receptor superfamily of transcription factors. As a nuclear receptor, AR functions as a molecular switch that becomes activated upon androgen binding, translocates to the nucleus, and regulates the expression of numerous target genes. Beyond its classical role in sexual development and reproductive function, AR is increasingly recognized as an important modulator of neuronal survival, differentiation, and vulnerability to neurodegenerative processes.
Function/Biology
The AR protein comprises several functional domains: an N-terminal domain (NTD) involved in transactivation, a DNA-binding domain (DBD) containing two zinc fingers for recognizing androgen response elements (AREs), a hinge region, and a ligand-binding domain (LBD) in the C-terminal region. When androgens enter target cells, they bind to the LBD with high affinity, inducing conformational changes that promote AR dissociation from heat shock proteins and nuclear translocation.
...Androgen Receptor Protein
Overview
The androgen receptor (AR) is a ligand-activated nuclear receptor that mediates the physiological effects of androgens, primarily testosterone and dihydrotestosterone (DHT), in target tissues throughout the body. The AR protein is encoded by the AR gene located on the X chromosome and belongs to the steroid receptor superfamily of transcription factors. As a nuclear receptor, AR functions as a molecular switch that becomes activated upon androgen binding, translocates to the nucleus, and regulates the expression of numerous target genes. Beyond its classical role in sexual development and reproductive function, AR is increasingly recognized as an important modulator of neuronal survival, differentiation, and vulnerability to neurodegenerative processes.
Function/Biology
The AR protein comprises several functional domains: an N-terminal domain (NTD) involved in transactivation, a DNA-binding domain (DBD) containing two zinc fingers for recognizing androgen response elements (AREs), a hinge region, and a ligand-binding domain (LBD) in the C-terminal region. When androgens enter target cells, they bind to the LBD with high affinity, inducing conformational changes that promote AR dissociation from heat shock proteins and nuclear translocation.
In the nucleus, AR dimerizes and binds to specific DNA sequences called ARE sequences located in promoter and enhancer regions of target genes. AR recruits coactivators and components of the transcriptional machinery to initiate or suppress gene expression. This classical genomic mechanism is supplemented by rapid, non-genomic effects where AR located at the cell membrane or in the cytoplasm triggers signaling cascades through phosphoinositide 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), and other kinase pathways within seconds to minutes.
Role in Neurodegeneration
AR signaling demonstrates complex and often neuroprotective roles in multiple neurodegenerative diseases. In Alzheimer's disease, reduced androgen signaling is associated with increased amyloid-beta accumulation and tau pathology, while AR activation promotes clearance mechanisms and reduces neuroinflammation. AR signaling appears particularly important in mitigating excitotoxicity and oxidative stress, two key pathological hallmarks of neurodegeneration.
In spinal muscular atrophy (SMA) and other motor neuron diseases, AR signaling supports motor neuron survival through promotion of neurotrophic factor production and mitochondrial function. Notably, AR contains a polyglutamine repeat tract in its NTD that can expand to pathogenic lengths, causing spinobulbar muscular atrophy (SBMA), a progressive motor neuron disease characterized by selective degeneration of lower motor neurons. The pathogenic AR-polyglutamine expansion leads to protein aggregation, mitochondrial dysfunction, and excitotoxic neuronal death.
Molecular Mechanisms
The neuroprotective mechanisms of AR involve multiple pathways. AR-mediated transcription upregulates anti-apoptotic genes, neurotrophic factors including nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), and antioxidant enzymes. AR also suppresses pro-inflammatory gene expression in microglial cells through transrepression of nuclear factor-kappa B (NF-κB) signaling.
In SBMA pathogenesis, polyglutamine expansion impairs the LBD's ability to interact with coactivators and enhances protein aggregation-prone conformations. Expanded AR aggregates sequester proteins involved in proteostasis and impair proteasomal and autophagic clearance. The aggregates also trigger endoplasmic reticulum stress and mitochondrial calcium dysregulation, ultimately leading to neuronal apoptosis through both intrinsic and extrinsic pathways.
Clinical/Research Significance
Understanding AR biology is clinically relevant for multiple conditions. In SBMA, expanded AR-polyglutamine represents a direct genetic cause of neurodegeneration, making it a valuable model for understanding polyglutamine diseases generally. Therapeutic approaches targeting AR aggregation, enhancing protein clearance, or modulating AR activity show promise in preclinical models.
For age-related neurodegenerative diseases, testosterone replacement therapy has been investigated as a potential neuroprotective strategy, though clinical evidence remains mixed and context-dependent. The sex-specific differences in neurodegeneration risk and progression increasingly implicate androgen signaling as a key biological variable.
- Polyglutamine diseases: Huntington's disease, dentatorubral-pallidoluysian atrophy (DRPLA)
- Neurotrophic factors: BDNF, NGF, GDNF
- Proteostasis components: Proteasome, autophagy machinery, heat shock proteins
- Related nuclear receptors: Estrogen receptor, glucocorticoid receptor
- Motor neuron disease: Amyotrophic lateral sclerosis (ALS), SMA
AlphaFold Structure
AlphaFold DB provides a predicted structure for AR / UniProt P10275 (model version 6): https://alphafold.ebi.ac.uk/entry/P10275.
AlphaFold reports a mean pLDDT confidence score of 57.25, indicating moderate confidence, so flexible or poorly constrained regions should be interpreted cautiously.
InterPro annotations highlight Nuclear hormone receptor, ligand-binding domain domain (669-900); Androgen receptor family (6-449); Zinc finger, nuclear hormone receptor-type domain (557-632).
PDB coordinates: https://alphafold.ebi.ac.uk/files/AF-P10275-F1-model_v6.pdb mmCIF coordinates: https://alphafold.ebi.ac.uk/files/AF-P10275-F1-model_v6.cif.
Use the prediction as structural context for target assessment; local low-pLDDT segments may reflect disorder, flexible linkers, or unresolved domain orientation rather than a stable fold.